跳至主要内容
临床试验/NCT03179202
NCT03179202已完成不适用

A Post-Market Study of Percutaneous Peripheral Nerve Stimulation (PNS) for the Treatment of Back Pain

SPR Therapeutics, Inc.16 个研究点 分布在 1 个国家目标入组 166 人开始时间: 2017年6月23日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
166
试验地点
16
主要终点
Number of Subjects That Experienced ≥30% Reduction in Average Low Back Pain Intensity

研究概览

简要总结

The purpose of this study is to evaluate the effectiveness of electrical stimulation (low levels of electricity) on low back pain. This study involves the SPRINT Peripheral Nerve Stimulation (PNS) system. The System delivers mild electrical stimulation to the nerves in the low back. The System includes up to four small wires (called "Leads") that are placed through the skin into the muscles in the low back. The wires attach to device(s) worn on the body that deliver stimulation (called Stimulators).

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • At least 21 years of age
  • Chronic low back pain

排除标准

  • Infection on or around the low back
  • Conditions with increased risk of infection (e.g., valvular heart disease, compromised immune system, history of recurrent skin infections)
  • Implanted electronic device
  • Body Mass Index (BMI) > 40

结局指标

主要结局

Number of Subjects That Experienced ≥30% Reduction in Average Low Back Pain Intensity

时间窗: Baseline and End of Treatment (EOT= 8-weeks post-start of treatment)

All subjects were asked to complete daily diaries to record their average pain intensity on each day of a 7-day period. The pain intensity question was excerpted from the Brief Pain Inventory-Short Form Question 5 (BPI-5). The BPI-5 uses an 11-point numerical rating scale where 0 represents "No Pain" and 10 represents "Pain as bad as you can imagine." For each subject, the mean score for the baseline and end of treatment (EOT) diary periods were calculated and percent reduction was determined. Subjects that achieved ≥30% reduction in pain, were considered successful.

Number of Subjects That Experienced at Least One Study-Related Adverse Event

时间窗: Up to 15 months for each subject from baseline to the last study visit

At each study visit following the baseline assessment at Visit 1, subjects were questioned if any changes in their medical status or condition has occurred since their previous visit. If the subject experienced a change that was an adverse event, an Adverse Event Form was completed by the site. The number of subjects that experienced at least one study-related adverse event is reported here.

次要结局

  • Patient Global Impression of Change (PGIC) Survey(8-weeks post-Start of Treatment (SOT))
  • Mean Change in Health-Related Quality of Life(Baseline and End of Treatment (EOT= 8-weeks post-start of treatment))
  • Worst Pain Intensity(Baseline and End of Treatment (EOT= 8-weeks post-start of treatment))
  • Oswestry Disability Index (ODI)(Baseline and End of Treatment (EOT= 8-weeks post-start of treatment))
  • Pain Interference(Baseline and End of Treatment (EOT= 8-weeks post-start of treatment))
  • Beck Depression Inventory (BDI-II)(Baseline and End of Treatment (EOT= 8-weeks post-start of treatment))

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (16)

Loading locations...

相似试验